|
WO03090798A1
|
|
Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
|
|
WO03090711A1
|
|
Compositions and methods for sublingual formulations of dihydroergotamine for the treatment of migraine
|
|
US2003198669A1
|
|
Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
|
|
US2003166677A1
|
|
Chlorinated heterocyclic compounds and methods of synthesis
|
|
US2003166679A1
|
|
Fluorinated heterocyclic compounds and methods of synthesis
|
|
US2003166676A1
|
|
Dichlorinated heterocyclic compounds and methods of synthesis
|
|
US2003166678A1
|
|
Carboxylated heterocyclic compounds and methods of synthesis
|
|
US2003191152A1
|
|
Use of monochloroflosequinan in the treatment of sexual dysfunction
|
|
US2003130311A1
|
|
Methods for the treatment of central nervous system disorders in certain patient groups
|
|
US2003105128A1
|
|
Treatment of sexual dysfunction in certain patient groups
|
|
CA2435876A1
|
|
The treatment of sexual dysfunction and cardiovascular disease with quinolinone enantiomers
|
|
US2003120075A1
|
|
Stereospecific enrichment of heterocyclic enantiomers
|
|
WO0218343A1
|
|
Method for synthesizing flosequinan from 4-fluoroanthranilic acid
|
|
US6541487B1
|
|
PDE III inhibitors for treating sexual dysfunction
|
